4.0 Article

Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis

Journal

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
Volume 41, Issue 3, Pages 489-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.rdc.2015.04.009

Keywords

Systemic sclerosis; Pulmonary arterial hypertension; Monitoring; Diagnosis

Categories

Funding

  1. Gilead
  2. United Therapeutics
  3. Pfizer
  4. Actelion
  5. Scleroderma Research Foundation
  6. Scleroderma Foundation

Ask authors/readers for more resources

Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with systemic sclerosis (SSc). Given the high prevalence and poor survival of SSc-PAH, and that aggressive management of mild disease may be associated with better outcomes, screening is critical. Right heart catheterization (RHO) is the gold standard for the definitive diagnosis of PAH, and should be performed in those patients in whom this diagnosis is suspected. Once a diagnosis of PAH is confirmed by RHO, treatment with PAH-specific therapies should be initiated as soon as possible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available